Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R.

Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.

2.

Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab.

Ladányi A, Kapuvári B, Papp E, Tóth E, Lövey J, Horváth K, Gődény M, Remenár É.

Head Neck. 2019 May;41(5):1237-1245. doi: 10.1002/hed.25546. Epub 2018 Dec 12.

PMID:
30548478
3.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.

PMID:
30383184
4.

[First report on successful application of nivolumab in Hungary for the treatment of locally recurrent head and neck squamous cell carcinoma].

Bellyei S, Bakó P, Orosz É, Molnár K, Remenár É, Mangel L.

Magy Onkol. 2018 Sep 26;62(3):175-178. Epub 2018 Jul 11. Hungarian.

5.

[Role of MRI and CT in the evaluation of postirradiation status and complications in head and neck cancer].

Gõdény M, Remenár É, Takácsi-Nagy Z, Petri K, Horváth K, Bõcs K, Manninger S, Andi J, Léránt G, Kásler M.

Magy Onkol. 2018 Sep 26;62(3):159-173. Epub 2018 Jul 22. Hungarian.

6.

[Retrospective analysis of papillary thyroid microcarcinoma cases treated between 2001 and 2010 in the Hungarian National Institute of Oncology].

Meilinger-Dobra M, Remenár É, Fröhlich G, Sinkovics I, Péter I, Boér A.

Magy Onkol. 2018 Sep 26;62(3):153-158. Epub 2018 Aug 31. Hungarian.

7.

Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.

Soulières D, Licitra L, Mesía R, Remenár É, Li SH, Karpenko A, Chol M, Wang YA, Solovieff N, Bourdeau L, Sellami D, Faivre S.

Clin Cancer Res. 2018 Jun 1;24(11):2505-2516. doi: 10.1158/1078-0432.CCR-17-2644. Epub 2018 Feb 28.

8.

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.

Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, Awada A, Clement PM, Fortpied C, Menis J, Vermorken JB.

Ann Oncol. 2017 Sep 1;28(9):2219-2224. doi: 10.1093/annonc/mdx300.

9.

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.

Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenár É, Degardin M, Pateras IS, Langendijk JA, van Herpen CML, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB.

Ann Oncol. 2017 Sep 1;28(9):2213-2218. doi: 10.1093/annonc/mdx320.

PMID:
28651338
10.

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L.

Lancet Oncol. 2017 Mar;18(3):323-335. doi: 10.1016/S1470-2045(17)30064-5. Epub 2017 Jan 26.

PMID:
28131786
11.

Impact of 3T multiparametric MRI and FDG-PET-CT in the evaluation of occult primary cancer with cervical node metastasis.

Gődény M, Lengyel Z, Polony G, Nagy ZT, Léránt G, Zámbó O, Remenár É, Tamás L, Kásler M.

Cancer Imaging. 2016 Nov 4;16(1):38.

12.

Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.

Takácsi-Nagy Z, Hitre E, Remenár É, Oberna F, Polgár C, Major T, Gödény M, Fodor J, Kásler M.

Strahlenther Onkol. 2015 Aug;191(8):635-41. doi: 10.1007/s00066-015-0829-z. Epub 2015 Mar 18.

PMID:
25782685
13.

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

Vermorken JB, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler TC, Keilholz U, Delord JP, Schafhausen P, Erfán J, Brümmendorf TH, Iglesias L, Bethe U, Hicking C, Clement PM.

Ann Oncol. 2014 Mar;25(3):682-8. doi: 10.1093/annonc/mdu003.

14.

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.

Hitre E, Budai B, Takácsi-Nagy Z, Rubovszky G, Tóth E, Remenár É, Polgár C, Láng I.

Br J Cancer. 2013 Sep 3;109(5):1117-22. doi: 10.1038/bjc.2013.468. Epub 2013 Aug 13.

15.

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.

Harrington K, Berrier A, Robinson M, Remenar E, Housset M, de Mendoza FH, Fayette J, Mehanna H, El-Hariry I, Compton N, Franklin N, Biswas-Baldwin N, Lau M, Legenne P, Kumar R.

Eur J Cancer. 2013 May;49(7):1609-18. doi: 10.1016/j.ejca.2012.11.023. Epub 2012 Dec 19.

PMID:
23265705
16.

[The role of PET-CT in detecting unknown primary tumour in patients with cervical lymph node metastases].

Fülöp M, Kásler M, Remenár E, Lengyel Z, Borbély K.

Magy Onkol. 2012 May;56(2):84-92. doi: MagyOnkol.2012.56.2.84. Epub 2012 Feb 21. Hungarian.

17.

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.

Licitra L, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB.

Ann Oncol. 2011 May;22(5):1078-87. doi: 10.1093/annonc/mdq588. Epub 2010 Nov 3.

18.

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).

van Herpen CM, Mauer ME, Mesia R, Degardin M, Jelic S, Coens C, Betka J, Bernier J, Remenar E, Stewart JS, Preiss JH, van den Weyngaert D, Bottomley A, Vermorken JB; EORTC Head and Neck Group.

Br J Cancer. 2010 Oct 12;103(8):1173-81. doi: 10.1038/sj.bjc.6605860. Epub 2010 Sep 14.

19.
20.

[Phoniatrics in the rehabilitation for head and neck cancer].

Mészáros K, Remenár E, Kásler M.

Magy Onkol. 2008 Sep;52(3):293-7. doi: 10.1556/MOnkol.52.2008.3.7. Review. Hungarian.

PMID:
18845500
21.

[Our clinical experience with fibula free flap].

Kásler M, Remenár E, Boér A, Iványi E, Fülöp M.

Magy Onkol. 2008 Sep;52(3):279-81. doi: 10.1556/MOnkol.52.2008.3.5. Hungarian.

PMID:
18845498
22.

[Applicable methods of reconstruction for the replacement of soft tissue after the radical resection of oral tumors].

Fülöp M, Boér A, Remenár E, Lengyel C, Kásler M.

Magy Onkol. 2008 Sep;52(3):261-7. doi: 10.1556/MOnkol.52.2008.3.3. Hungarian.

PMID:
18845496
23.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R.

N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.

24.

[Laser surgery of head and neck lesions at the National Institute of Oncology, Budapest].

Kásler M, Remenár E, Lengyel CG, Boér A.

Magy Onkol. 2008 Jun;52(2):171-6. doi: 10.1556/MOnkol.52.2008.2.5. Hungarian.

PMID:
18640893
25.

[Problems occurring in the application of cytogenetic biomarkers for alcoholics with and without malignant diseases].

Gundy S, Székely G, Farkas G, Pulay A, Remenár E.

Magy Onkol. 2008 Jun;52(2):153-61. doi: 10.1556/MOnkol.52.2008.2.3. Hungarian.

PMID:
18640891
26.

Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer.

Csuka O, Remenár E, Koronczay K, Doleschall Z, Németh G.

Pathol Oncol Res. 1997 Sep;3(3):204-10. doi: 10.1007/BF02899922.

27.

Increase of hypophyseal hormone levels in male head and neck cancer patients.

Remenár E, Számel I, Budai B, Vincze B, Gaudi I, Gundy S, Kásler M.

Pathol Oncol Res. 2007;13(4):341-4. Epub 2007 Dec 25.

28.

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group.

N Engl J Med. 2007 Oct 25;357(17):1695-704.

29.

RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age.

Olasz J, Juhász A, Remenár E, Engi H, Bak M, Csuka O, Kásler M.

Oncol Rep. 2007 Jul;18(1):105-12.

PMID:
17549354
30.

Molecular identification, expression and prognostic role of estrogen- and progesterone receptors in head and neck cancer.

Lukits J, Remenár E, Rásó E, Ladányi A, Kásler M, Tímár J.

Int J Oncol. 2007 Jan;30(1):155-60.

PMID:
17143524
31.

Antiangiogenic effects of radiotherapy but not initial microvessel density predict survival in inoperable oropharyngeal squamous cell carcinoma.

Lövey J, Lukits J, Remenár E, Koronczay K, Kásler M, Németh G, Tímár J.

Strahlenther Onkol. 2006 Mar;182(3):149-56.

PMID:
16520909
32.

[Radiation-induced alterations in microvessel density as predictor of treatment efficiency in oropharyngeal cancer].

Lövey J, Lukits J, Remenár E, Koronczay K, Kásler M, Németh G, Tímár J.

Magy Onkol. 2005;49(4):307-13. Epub 2006 Mar 6. Hungarian.

33.

Mutagen sensitivity of patients with cancer at different sites of the head and neck.

Székely G, Remenár E, Kásler M, Gundy S.

Mutagenesis. 2005 Sep;20(5):381-5. Epub 2005 Aug 16.

PMID:
16105906
34.

Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.

Tímár J, Ladányi A, Forster-Horváth C, Lukits J, Döme B, Remenár E, Godény M, Kásler M, Bencsik B, Répássy G, Szabó G, Velich N, Suba Z, Elo J, Balatoni Z, Pócza K, Zemplén B, Chretien P, Talor E.

J Clin Oncol. 2005 May 20;23(15):3421-32.

PMID:
15908653
35.

Progression of head and neck squamous cell cancer.

Tímár J, Csuka O, Remenár E, Répássy G, Kásler M.

Cancer Metastasis Rev. 2005 Jan;24(1):107-27. Review.

PMID:
15785876
36.

Interstitial high-dose-rate brachytherapy in the treatment of base of tongue carcinoma.

Takácsi-Nagy Z, Polgár C, Oberna F, Somogyi A, Major T, Remenár E, Fodor J, Kásler M, Németh G.

Strahlenther Onkol. 2004 Dec;180(12):768-75.

PMID:
15592696
37.

[Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].

Vincze B, Sinkovics I, Keresztes S, Gergye M, Boér A, Remenár E, Péter I, Szentirmay Z, Kremmer T, Kásler M.

Magy Onkol. 2004;48(1):27-34. Epub 2004 Apr 23. Hungarian.

38.

The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.

Tímár J, Forster-Horváth C, Lukits J, Döme B, Ladányi A, Remenár E, Kásler M, Bencsik M, Répássy G, Szabó G, Velich N, Suba Z, Elõ J, Balatoni Z, Bajtai A, Chretien P, Talor E.

Laryngoscope. 2003 Dec;113(12):2206-17.

PMID:
14660929
39.

[Role of CT and MR examinations in the assessment of nasopharyngeal tumors].

Gödény M, Lengyel E, Polony I, Esik O, Somogyi A, Remenár E, Németh G, Kásler M.

Orv Hetil. 2003 Oct 19;144(42):2065-71. Hungarian. No abstract available.

PMID:
14658418
40.

[Prognostic significance of sex steroid and hypophyseal hormones in head and neck squamous cell carcinoma].

Remenár E, Számel I, Budai B, Orosz Z, Gaudi I, Kásler M, Gundy S.

Magy Onkol. 2003;47(2):155-9. Epub 2003 Sep 16. Hungarian.

41.

Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer.

Lövey J, Koronczay K, Remenár E, Csuka O, Németh G.

Radiother Oncol. 2003 Aug;68(2):171-4.

PMID:
12972312
42.

Malignant mucosal melanoma of the head and neck.

Lengyel E, Gilde K, Remenár E, Esik O.

Pathol Oncol Res. 2003;9(1):7-12. Epub 2003 Apr 18. Review.

43.

[Squamous cell carcinoma of the larynx and hypopharynx--classification, investigation and therapy].

Bánhidy F, Czigner J, Eló J, Kásler M, Mayer A, Németh G, Pólus K, Remenár E.

Magy Onkol. 2002;46(4):301-5. Review. Hungarian. No abstract available.

44.

[Serum levels of sex steroid and pituitary hormones in chronic alcoholics and head and neck cancer patients as compared to normal controls].

Remenár E, Számel I, Budai B, Gaudi I, Kásler M, Gundy S.

Magy Onkol. 2002;46(4):329-32. Epub 2003 Feb 1. Hungarian.

45.

Does the bleomycin sensitivity assay express cancer phenotype?

Székely G, Remenár E, Kásler M, Gundy S.

Mutagenesis. 2003 Jan;18(1):59-63.

PMID:
12473736
46.
47.

[Low-dose Taxol radiosensitization in locally advanced head and neck cancers]

Lövey J, Koronczay K, Remenár E, Csuka O, Németh G.

Magy Onkol. 2001;45(2):201-206. Hungarian.

48.

[Neoadjuvant chemotherapy in head and neck cancer]

Koltai P, Remenár E, Boér A, Fülöp M, Koltai L, Oberna F, Udvaros I, Pólus K, Kásler M.

Magy Onkol. 2001;45(2):197-199. Hungarian.

49.

[Radial forearm and fibula free flap reconstruction after radical resection of head and neck malignancies]

Fülöp M, Remenár E, Oberna F, Boér A, Iványi E, Pólus K, Kásler M.

Magy Onkol. 2001;45(2):177-180. Hungarian.

50.

[Genetic marker analysis in head and neck cancer]

Csuka O, Olasz J, Juhász A, Hargitai A, Remenár E, Kásler M.

Magy Onkol. 2001;45(2):161-167. Hungarian.

Supplemental Content

Loading ...
Support Center